Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CTN Accepted for SymBio’s Japan Phase 1 Trial of Rigosertib (SyB L-1101)

Published: Thursday, September 27, 2012
Last Updated: Thursday, September 27, 2012
Bookmark and Share
U.S. FDA grants orphan drug designation for using rigosertib in MDS and pancreatic cancer.

SymBio Pharmaceuticals Limited has announced that clinical trial notification (CTN) has been accepted for its Phase 1 clinical trial using rigosertib (SyB L-1101) in refractory and relapsed myelodysplastic syndrome (MDS) patients.

Onconova Therapeutics, Inc., a U.S.-based biopharmaceutical company which has licensed rigosertib to SymBio, is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India in hematological cancers and solid tumors.

A pivotal Phase III trial in refractory/relapsed MDS patients was initiated under a Special Protocol Assessment from the U.S. FDA and is underway at more than 50 centers in the U.S. and Europe.

The U.S. FDA has granted orphan drug designation for the use of rigosertib in MDS and pancreatic cancer.

In addition to the intravenous product in advanced-stage development and with the successful completion of two Phase I trials, an oral formulation of rigosertib is being developed for frontline MDS in Phase II trials and other indications.

To date, more than 500 cancer patients have been treated with rigosertib in Phase I, II and III clinical trials conducted in the U.S., EU and India.

As well as this first trial for the treatment of refractory and relapsed MDS patients, SymBio is planning to initiate a Phase I clinical trial for the treatment of frontline MDS using the oral form of rigosertib (SyB C-1101) based on promising results generated in U.S. Phase II clinical trials.

Patients with MDS often require frequent blood transfusions due to the development of severe anemia (decrease in number of red blood cells), with approximately one third of patients progressing to acute myelogenous leukemia (AML).

MDS remains an underserved therapeutic area with few available treatment options for patients, hence SymBio is moving rigosertib through clinical development as nimbly as possible.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SymBio Initiates Japanese Phase I Trial of Oral Rigosertib (SyB C-1101) in Frontline MDS
U.S. FDA has granted orphan drug designation for the use of rigosertib in MDS.
Thursday, July 25, 2013
Scientific News
New Way of Displaying 3D Molecular Structures
Metal-organic frameworks provide a new platform for solving the structure of hard-to-study samples.
Agent Blocks Pain Without Morphine's Side Effects
Scientists have synthesised a molecule with specific pain-relief properties and has shown its efficacy in mice.
Cutting the Cost of Drug-Building Chemicals
EPFL scientists have developed a method to produce aryl-containing amines in a cheap and easily scalable way.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Accessing Metabolic Information with Mass Spec
Scientists at the Helmholtz Zentrum München have developed a new mass spectrometry imaging method which, for the first time, makes it possible to analyze hundreds of metabolites in fixed tissue samples.
Simplifying Gene Testing Access for Ovarian Cancer Patients
Simplifying access to gene testing for women with ovarian cancer improves treatment choices and could save lives.
New Protein Model Could Accelerate Drug Development
Stony Brook-led international research team creates ultra-fast approach to model protein interactions.
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!